Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis

Cancer Research

Volumn 68, Issue 6, 2008, Pages 1797-1808

  De Nigris, Filomena ^a   Rossiello, Raffaele ^a   Schiano, Concetta ^a   Arra, Claudio ^b   Williams Ignarro, Sharon ^c   Barbieri, Antonio ^b   Lanza, Alessandro ^a   Balestrieri, Antonio ^a   Giuliano, Maria Teresa ^a   Ignarro, Louis J ^c   Napoli, Claudio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MATRIGEL; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR YY1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SILENCING; HISTOLOGY; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SERIAL ANALYSIS OF GENE EXPRESSION; UNINDEXED SEQUENCE;

ANIMALS; BONE NEOPLASMS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; RECEPTORS, CXCR4; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; YY1 TRANSCRIPTION FACTOR;

EID: 40949120250     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5582     Document Type: Article

References (40)

1. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004;429:286-91.
2. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
3. Wang LL. Biology of osteogenic sarcoma. Cancer J 2005;11:294-05.
4. Wunder JS, Nielsen TO, Maki RG, et al. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007;8:513-24.
5. de Nigris F, Botti C, de Chiara A, et al. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer 2006;42:2420-4.
6. de Nigris F, Botti C, Rossiello R, Crimi E, Sica V, Napoli C. Cooperation between Myc and YY1 provides novel silencing transcriptional targets of α3β1-integrin in tumour cells. Oncogene 2007;26:382-94.
7. Zaidi SK, Young DW, Javed A, et al. Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 2007;7:454-63.
8. Kilarski WW, Bikfalvi A. Recent developments in tumour angiogenesis. Curr Pharm Biotechnol 2007;8:3-9.
9. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001;345:833-5.
10. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14:171-9.
11. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007;1768:952-63.
12. de Nigris F, Balestrieri ML, Williams-Ignarro S, et al. Therapeutic effects of autologous bone marrow cells and metabolic intervention in the ischemic hindlimb of spontaneously hypertensive rats involve reduced cell senescence and CXCR4/Akt/eNOS pathways. J Cardiovasc Pharmacol 2007;50:424-33.
13. Lee BC, Lee TH, Zagozdzon R, Avraham S, Usheva A, Avraham HK. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 impairs CXCR4/CXCL12 (SDF-1a)-mediated breast cancer cell migration. Cancer Res 2005;65:2840-45.
14. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006;19:738-45.
15. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal derived factor 1 system during osteosarcoma tumour progression. Clin Cancer Res 2005;11:490-97.
16. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patient with osteosarcoma. Clin Cancer Res 2005;11:25621-27.
17. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62:7328-34.
18. de Nigris F, Cerutti J, Morelli C, et al. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer 2002;86:917-23.
19. de Nigris F, Mega T, Berger N, et al. Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. Cancer Res 2001;61:2267-75.
20. de Nigris F, Visconti R, Cerutti J, et al. Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas. Cancer Res 1998;58:4745-51.
21. Napoli C, Glass CK, Witztum JL, et al. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999;354:1234-41.
22. Lavker RM, Dong G, Zheng PS, Murphy GF. Hairless micropig skin. A novel model for studies of cutaneous biology. Am J Pathol 1991;138:687-97.
23. Napoli C, Lerman LO, Sica V, Lerman A, Tajana G, de Nigris F. Microarray analysis: a novel research tool for cardiovascular scientists and physicians. Heart 2003;89:597-04.
24. Napoli C, Sica V, de Nigris F. New advances in microarrays: finding the genes causally involved in disease. Methods Mol Med 2005;108:215-33.
25. Lamberti M, Perfetto B, Costabile T, et al. In vitro evaluation of matrix metalloproteinases as predictive testing for nickel, a model sensitizing agent. Toxicol Appl Pharmacol 2004;195:321-30.
26. Wirzenius M, Tammela T, Uutela M, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 2007;204:1431-40.
27. Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights to cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis 2006;23:367-80.
28. Affar EL B, Gay F, Shi Y, et al. Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol Cell Biol 2006;26:3565-81.
29. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
30. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;85:683-93.
31. Farnebo F, Piehl F, Lagercrantz J. Restricted expression pattern of vegf-d in the adult and fetal mouse: high expression in the embryonic lung. Biochem Biophys Res Commun 1999;257:891-4.
32. Akahane M, Akahane T, Matheny SL, et al. Vascular endothelial growth factor-D is a survival factor for human breast carcinoma cells. Int J Cancer 2006;118:841-9.
33. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203-6.
34. Engl T, Relja B, Marian D, et al. CXCR4 chemokine receptor mediates prostate tumour cell adhesion through α5 and β3 integrins. Neoplasia 2006;8:290-301.
35. Pan J, Mestas J, Burdick MD, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006;5:56.
36. de Nigris F, Sica V, Herrmann J, et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. Cell Cycle 2003;2:325-8.
37. de Nigris F, Balestrieri ML, Napoli C. Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle 2006;5:1621-8.
38. Balestrieri ML, Napoli C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer 2007;43:1242-50.
39. Rajgopal A, Young DW, Mujeeb KA, et al. Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells. J Cell Biochem 2007;100:1509-17.
40. Abbondanza C, de Nigris F, de Rosa C, Rossiello R, Puca GA, Napoli C. Silencing of YY1 down-regulates RIZ1 promoter in human osteosarcoma. Oncol Res. In press 2008.